Michael S. Isakoff

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

Sigbjørn Smeland, Stefan Bielack, Jeremy Whelan et al. · European Journal of Cancer · 2019 · 700 citations · Full text

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

Neyssa Marina, Sigbjørn Smeland, Stefan Bielack et al. · The Lancet Oncology · 2016 · 511 citations · Full text

Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a “beard” distribution

Seth J. Orlow, Michael S. Isakoff, Francine Blei · The Journal of Pediatrics · 1997 · 296 citations · Full text

Symptomatic Hemangiomas, Pediatric Patients, Otolaryngology +13

Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation

Michael S. Isakoff, Courtney G. Sansam, Pablo Tamayo et al. · Proceedings of the National Academy of Sciences · 2005 · 216 citations · Full text

Oncogenic Transformation, Cell Cycle, Cancer Biology +18

A phase II trial of a multi‐agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer

Nathan Robison, Federico Campigotto, Peter Manley et al. · Pediatric Blood & Cancer · 2013 · 149 citations · Full text